MIF and breast carcinoma: Patients with strong cytosolic MIF expression in the breast cancer tissue (IRS = 6–12) showed a highly significant increase in overall survival (OS) compared to the MIF low expresser group with an IRS = 0–4 (5-year OS = 67% versus 50%, respectively; p = 0.0019; Figure 7 and Table 2).